VENTOLIN HFA Drug Patent Profile
✉ Email this page to a colleague
When do Ventolin Hfa patents expire, and when can generic versions of Ventolin Hfa launch?
Ventolin Hfa is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in VENTOLIN HFA is albuterol sulfate. There are thirty-eight drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the albuterol sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ventolin Hfa
A generic version of VENTOLIN HFA was approved as albuterol sulfate by SUN PHARM INDUSTRIES on December 5th, 1989.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VENTOLIN HFA?
- What are the global sales for VENTOLIN HFA?
- What is Average Wholesale Price for VENTOLIN HFA?
Summary for VENTOLIN HFA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 10 |
| Raw Ingredient (Bulk) Api Vendors: | 81 |
| Clinical Trials: | 51 |
| Patent Applications: | 5,404 |
| Drug Prices: | Drug price information for VENTOLIN HFA |
| Drug Sales Revenues: | Drug sales revenues for VENTOLIN HFA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VENTOLIN HFA |
| What excipients (inactive ingredients) are in VENTOLIN HFA? | VENTOLIN HFA excipients list |
| DailyMed Link: | VENTOLIN HFA at DailyMed |
See drug prices for VENTOLIN HFA
Recent Clinical Trials for VENTOLIN HFA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Alberta | Phase 1 |
| Canisius-Wilhelmina Hospital | Phase 3 |
| Hat Yai Medical Education Center | Phase 3 |
Pharmacology for VENTOLIN HFA
| Drug Class | beta2-Adrenergic Agonist |
| Mechanism of Action | Adrenergic beta2-Agonists |
US Patents and Regulatory Information for VENTOLIN HFA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | VENTOLIN HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 020983-001 | Apr 19, 2001 | BX | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VENTOLIN HFA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | VENTOLIN HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 020983-001 | Apr 19, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline | VENTOLIN HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 020983-001 | Apr 19, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline | VENTOLIN HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 020983-001 | Apr 19, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline | VENTOLIN HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 020983-001 | Apr 19, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| Glaxosmithkline | VENTOLIN HFA | albuterol sulfate | AEROSOL, METERED;INHALATION | 020983-001 | Apr 19, 2001 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VENTOLIN HFA
See the table below for patents covering VENTOLIN HFA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2005530259 | ⤷ Sign Up | |
| New Zealand | 501379 | Dispenser with dosage counter with container and actuation indicator reversably removable as one unit | ⤷ Sign Up |
| Canada | 2489554 | INDICATEUR D'ACTIONNEMENT POUR DISPOSITIF DISTRIBUTEUR (ACTUATION INDICATOR FOR A DISPENSING DEVICE) | ⤷ Sign Up |
| Denmark | 1516283 | ⤷ Sign Up | |
| European Patent Office | 1301230 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
